Aortitis: an update.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Aorta
/ pathology
Aortitis
/ diagnosis
Female
Follow-Up Studies
Giant Cell Arteritis
/ diagnosis
Humans
Immunoglobulin G4-Related Disease
/ epidemiology
Immunosuppressive Agents
/ therapeutic use
Janus Kinases
/ metabolism
Leflunomide
/ therapeutic use
Male
Positron Emission Tomography Computed Tomography
/ methods
Takayasu Arteritis
/ diagnosis
Ultrasonography
/ methods
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
14
11
2020
medline:
23
7
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
Aortitis is the inflammation of the aorta due to various causes. Clinical presentations vary as well as the imaging findings. Exact pathogenetic mechanisms or triggering factors, as well as the best diagnostic and monitoring modalities and treatment strategies, are yet to be elucidated. We reviewed recent studies in aortitis and associated diseases. Multiple cohort studies reporting long-term outcomes in patients with noninfectious aortitis were recently published. Comparative features of isolated aortitis were described. Six angiographic clusters for giant cell arteritis and Takayasu have been identified. New classification criteria have been proposed for IgG4-related disease by a data-driven method. The ultrasonographic slope sign and a halo score were described as specific imaging parameters in giant cell arteritis. The promising role of PET-computed tomography, not only in the diagnosis of aortitis but also in monitoring disease activity, has been noted. Results of in-vitro studies on Janus kinase (JAK)/signal transducers and activators of transcription and mammalian target of rapamycin (mTOR) pathways, comparative studies with leflunomide as an induction therapy, and a long-term follow-up study with tocilizumab may contribute to the management of Takayasu arteritis. An impressive number of studies have addressed aortitis in recent years. However, there still is a lack of robust data on causes, monitoring disease activity by imaging and biomarkers, and drugs providing steroid-free remission in noninfectious aortitis.
Identifiants
pubmed: 33186247
doi: 10.1097/BOR.0000000000000762
pii: 00002281-202101000-00006
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunosuppressive Agents
0
Janus Kinases
EC 2.7.10.2
Leflunomide
G162GK9U4W
tocilizumab
I031V2H011
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-40Références
Gornik HL, Creager MAJC. Aortitis. Circulation 2008; 117:3039–3051.
Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculidities. Best Pract Res Clin Rheumatol 2010; 24:871–883.
Stone JR, Bruneval P, Angelini A, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol 2015; 24:267–278.
Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 77:636–643.
Quimson L, Mayer A, Capponi S, et al. Rheumatology. Comparison of aortitis versus noninflammatory aortic aneurysms among patients who undergo open aortic aneurysm repair. Arthritis Rheumatol 2020; 72:1154–1159.
Ferfar Y, Morinet S, Espitia O, et al. Long-term outcome and prognosis factors of isolated aortitis. Circulation 2020; 142:92–94.
Clifford AH, Arafat A, Idrees JJ, et al. Outcomes among 196 patients with noninfectious proximal aortitis. Arthritis Rheumatol 2019; 71:2112–2120.
Ben-Shabat N, Tiosano S, Shovman O, et al. Mortality among patients with giant cell arteritis: a large-scale population-based cohort study. J Rheumatol 2020; 47:1385–1391.
Brekke LK, Fevang BT, Diamantopoulos AP, et al. Survival and death causes of patients with giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther 2019; 21:154.
Egebjerg K, Baslund B, Obel N, Faurschou M. Mortality and cardiovascular morbidity among patients diagnosed with Takayasu's arteritis: a Danish nationwide cohort study. Clin Exp Rheumatol 2020; 38:91–94.
Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom. Ann Rheum Dis 2006; 65:1093–1098.
Kisza K, Murchison AP, Dai Y, et al. Giant cell arteritis incidence: analysis by season and year in mid-Atlantic United States. Clin Exp Ophthalmol 2013; 41:577–581.
Gokoffski KK, Chatterjee A, Khaderi SK. Seasonal incidence of biopsy-proven giant cell arteritis: a 20-year retrospective study of the University of California Davis Medical System. Clin Exp Rheumatol 2019; 37: (Suppl 117): 90–97.
Erdogan M, Esatoglu SN, Hatemi G, Hamuryudan V. Aortic involvement in relapsing polychondritis: case-based review. Rheumatol Int 2019; [Epub ahead of print].
Taimen K, Heino S, Kohonen I, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatol Adv Pract 2020; 4:rkaa004.
Sugai Y, Toyoguchi Y, Kanoto M, et al. Clinical and image features: large-vessel vasculitis after granulocyte colony stimulating factor administration. Acta Radiol 2020; 284185120931685[Epub ahead of print].
Crout TM, Lennep DS, Kishore S, Majithia V. Systemic vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep 2019; 21:28.
Yoshizaki T, Itoh S, Yamaguchi S, et al. IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice. Sci Rep 2019; 9:17067.
Li T, Gao N, Cui W, et al. Natural killer cells and their function in Takayasu's arteritis. Clin Exp Rheumatol 2020; 38: (Suppl 124): 84–90.
Desbois AC, Cacoub P, Leroyer AS, et al. Immunomodulatory role of interleukin-33 in large vessel vasculitis. Sci Rep 2020; 10:6405.
Dos Santos JP, Artigiani Neto R, Mangueira CLP, et al. Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. Clin Exp Immunol 2020; [Epub ahead of print].
Savioli B, Abdulahad WH, Brouwer E, et al. Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? Autoimmun Rev 2017; 16:1071–1078.
Régnier P, Le Joncour A, Maciejewski-Duval A, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis 2020; 79:951–959.
Zhang J, Zhao L, Wang J, et al. Targeting mechanistic target of rapamycin complex 1 restricts proinflammatory T cell differentiation and ameliorates takayasu arteritis. Arth Rheumatol 2020; 72:303–315.
Goel R, Gribbons KB, Carette S, et al. Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. Rheumatology 2020; 59:1118–1127.
Quinn KA, Gribbons KB, Carette S, et al. Patterns of clinical presentation in Takayasu's arteritis. Semin Arthritis Rheum 2020; 50:576–581.
Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine 2009; 88:221–226.
Gribbons KB, Ponte C, Carette S, et al. Patterns of arterial disease in Takayasu's arteritis and giant cell arteritis. Arthritis Care Res 2020; 72:1615–1624.
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2020; 79:77–87.
Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019; 78:406–412.
Peng L, Zhang P, Li J, et al. IgG4-related aortitis/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. Arthritis Res Ther 2020; 22:103.
Aydin SZ, Robson JC, Sreih AG, et al. Update on outcome measure development in large-vessel vasculitis: report from OMERACT. J Rheumatol 2019; 46:1198–1201.
Rimland CA, Quinn KA, Rosenblum JS, et al. Outcome measures in large vessel vasculitis: relationship between patient-, physician-, imaging-, and laboratory-based assessments. Arthritis Care Res 2020; 72:1296–1304.
Sammel AM, Hsiao E, Schembri G, et al. Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arth Rheumatol 2019; 71:1319–1328.
Hay B, Mariano-Goulart D, Bourdon A, et al. Diagnostic performance of (18)F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy. Ann Nucl Med 2019; 33:512–520.
Kang F, Han Q, Zhou X, et al. Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients. Eur J Nucl Med Mol Imaging 2020; [Epub ahead of print].
Quinn KA, Rosenblum JS, Rimland CA, et al. Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis. Semin Arthritis Rheum 2020; 50:71–76.
Michailidou D, Rosenblum JS, Rimland CA, et al. Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis. Ann Rheum Dis 2020; 79:262–267.
Tarkin JM, Wall C, Gopalan D, et al. Novel approach to imaging active Takayasu arteritis using somatostatin receptor positron emission tomography/magnetic resonance imaging. Circ Cardiovasc Imaging 2020; 13:e010389.
Dasgupta B, Smith K, Khan AAS, et al. ‘Slope sign’: a feature of large vessel vasculitis? Ann Rheum Dis 2019; 78:1738.
Milchert M, Brzosko M, editors. Slide sign: a novel sonographic sign of extracranial giant cell arteritis. Third International Symposium and Workshop on GCA, PMR and LVV, Southend-on-Sea, Essex, UK; 2016.
Milchert M, Brzosko M, Bull Haaversen A, Diamantopoulos AP. Correspondence to ‘Slope sign’: a feature of large vessel vasculitis? Ann Rheum Dis 2019; [Epub ahead of print].
Hop H, Mulder DJ, Sandovici M, et al. Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis. Rheumatology 2020; [Epub ahead of print].
van der Geest KSM, Borg F, Kayani A, et al. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis 2020; 79:393–399.
Germanò G, Macchioni P, Possemato N, et al. Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings. Arth Care Res 2017; 69:143–149.
Wang Y, Wang YH, Tian XP, et al. Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients. Clin Rheumatol 2020; 39:1229–1235.
Li Z, Zheng Z, Ding J, et al. Contrast-enhanced ultrasonography for monitoring arterial inflammation in Takayasu arteritis. J Rheumatol 2019; 46:616–622.
Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79:19–30.
Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018; 77:348–354.
Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology 2020; 59:2427–2434.
Mekinian A, Saadoun D, Vicaut E, et al. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 2020; 22:218.
Dai X, Cui X, Sun Y, et al. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. Ther Adv Chronic Dis 2020; 11:2040622320922019.
Laurent C, Marjanovic Z, Ricard L, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2020; 55:2109–13.
Zheng T, Zhu S, Ou JF, et al. Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu's arteritis. J Invest Surg 2019; 32:220–227.
Mousa A, Sharabi A, Elkalla MA, et al. Prophylactic prosthetic wrapping for vascular anastomosis in patients with Behçet's aortic aneurysms: an experience from a resource-challenged setting. Int Angiol 2019; 38:484–493.
Wang H, Zhang Y, Shen Z, et al. Comparing the effects of different management strategies on long-term outcomes for significant coronary stenosis in patients with Takayasu arteritis. Int J Cardiol 2020; 306:1–7.